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Abstract
Background: Autism is a highly heritable complex neurodevelopmental disorder, therefore
identifying its genetic basis has been challenging. To date, numerous susceptibility genes and
chromosomal abnormalities have been reported in association with autism, but most discoveries
either fail to be replicated or account for a small effect. Thus, in most cases the underlying causative
genetic mechanisms are not fully understood. In the present work, the Autism Genetic Database
(AGD) was developed as a literature-driven, web-based, and easy to access database designed with
the aim of creating a comprehensive repository for all the currently reported genes and genomic
copy number variations (CNVs) associated with autism in order to further facilitate the assessment
of these autism susceptibility genetic factors.
Description: AGD is a relational database that organizes data resulting from exhaustive literature
searches for reported susceptibility genes and CNVs associated with autism. Furthermore,
genomic information about human fragile sites and noncoding RNAs was also downloaded and
parsed from miRBase, snoRNA-LBME-db, piRNABank, and the MIT/ICBP siRNA database. A web
client genome browser enables viewing of the features while a web client query tool provides
access to more specific information for the features. When applicable, links to external databases
including GenBank, PubMed, miRBase, snoRNA-LBME-db, piRNABank, and the MIT siRNA
database are provided.
Conclusion: AGD comprises a comprehensive list of susceptibility genes and copy number
variations reported to-date in association with autism, as well as all known human noncoding RNA
genes and fragile sites. Such a unique and inclusive autism genetic database will facilitate the
evaluation of autism susceptibility factors in relation to known human noncoding RNAs and fragile
sites, impacting on human diseases. As a result, this new autism database offers a valuable tool for
the research community to evaluate genetic findings for this complex multifactorial disorder in an
integrated format. AGD provides a genome browser and a web based query client for conveniently
selecting features of interest. Access to AGD is freely available at http://wren.bcf.ku.edu/.
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Autism is an early onset neurodevelopmental disorder
belonging to a group of conditions known as autism spec-
trum disorders (ASDs) which includes classical autism,
pervasive developmental disorder-not otherwise specified
(PDD-NOS), and Asperger syndrome [1]. ASDs are genet-
ically and phenotypically heterogeneous with a variable
degree of severity and symptomology. The prevalence of
autism spectrum disorders has risen in recent decades to
6.7 per 1000 children in the United States [2]. Diagnosis
of autism is defined by significant impairments in three
developmental domains: reciprocal social behavior, com-
munication, and repetitive stereotypic behaviors or
restricted interests [1].
Several candidate genes have been linked to this highly
heritable disorder, but the etiology of most cases remains
unknown. Linkage analyses for autism susceptibility loci
have suggested the involvement of multiple genes from
different chromosomes. Despite the completion of several
genome-wide linkage studies for autism, most of the loci
identified have not been replicated. Furthermore, associa-
tion of several candidate genes have been reported and
examined in subjects with autism, mainly with no conclu-
sive evidence. As a result, a number of autism susceptibil-
ity nucleotide changes have been reported but have not
been replicated. These inconsistent results could be in part
a reflection of the clinical heterogeneity and varying
degrees of severity in ASD.
For example, in 2003 the first evidence of mutations in
coding sequences of two X-linked neuroligin genes,
NLGN3 and NLGN4, were reported in individuals with
autism spectrum disorders [3]. Neuroligins are cell adhe-
sion proteins involved in the formation of neural syn-
apses [4]. Electrophysiological studies on mutant
neuroligins carrying deletions in either the cytoplasmic
tail or in the esterase-homology domain showed the criti-
cal role of the neuroligin genes in maintaining a func-
tional balance between excitatory and inhibitory synapses
in hippocampal neurons [5]. This finding resulted in the
conclusion that neuroligin defects lead to selective loss of
inhibitory function and abnormal excitatory/inhibitory
balance in neurons. Such a defect is believed to play a role
in autism [5,6].
Despite strong supportive evidence for the role of these
neuroligin genes in synaptic function, only a few causal
mutations in the NLGN3 and NLGN4 genes have been
identified in subjects with autism, suggesting that these
mutations are not common and occur at a low frequency
in the autistic population (less than 1%) [7-15]. There-
fore, at the population level the actual proportion of
known genetic variants or changes contributing to the eti-
ology of autism remains to be determined, since most
identified genetic causes may account for a small effect. A
fact that is expected, given the clinical heterogeneity and
varying degrees of severity in this complex disorder, which
demands the evaluation of multiple factors using inte-
grated approaches.
Furthermore, genomic DNA copy number variations
(CNVs) including small deletions and duplications of
chromosomes, which may affect gene function have been
recently reported in association with complex disorders
such as autism [16-19]. In a recent review, the association
of CNVs with neuropsychiatric conditions including ASD
was discussed by Cook and Scherer [20]. One conclusion
of this review paper was that while it is more likely for a
de novo than an inherited CNV to be pathogenic, the final
causal effect of CNVs might be influenced by other cis- or
trans-acting factors in a particular genomic environment,
representing in an incomplete penetrance or a variable
expressivity for a given CNV. This suggests that due to the
complexity of neuropsychiatric disorders, the evaluation
of biological relevance of CNVs should be considered in
an integrated context [20]. For a recent review discussing
advances in autism genetics see Abrahams and
Geschwind [21].
Recent developments in molecular genetic technologies
and knowledge have introduced new avenues to be
explored, in particular for complex disorders. A good
example is gene regulatory factors such as noncoding
RNAs (ncRNAs) which are highly expressed in the nervous
system [22]. An estimated 98% of the transcriptional out-
put in humans and other mammals consist of ncRNAs
that do not code for protein but have other functions in
cells [23]. Four main groups of ncRNAs include microR-
NAs, snoRNAs, piRNAs, and siRNAs. A brief description of
each type and their relevance to human disease is pro-
vided here.
microRNAs are small RNA molecules of approximately 22
nt that regulate gene expression by binding to the 3'-
untranslated regions (3'UTR) of target mRNA(s), directing
translational repression or transcript degradation [24]. It
is estimated that up to 30% of human genes may be
microRNA targets [25]. Small nucleolar RNAs (snoRNAs)
direct the site-specific modification of nucleotides in tar-
get ribosomal RNAs (rRNAs) [26]. However, some
snoRNA (known as orphan snoRNAs) lack known targets
for rRNA. Two classes of snoRNA can be distinguished
based on their conserved sequence motifs: H/ACA box
snoRNAs and C/D box snoRNAs. The C/D box snoRNAs
contain four conserved motifs called boxes C, C', D, and
D', with a 10-21 nucleotide long antisense element
located upstream of the D and/or D' boxes.
One of the most studied snoRNAs in humans is HBII-52,
located at chromosome 15q11 [27]. In addition to HBII-
52, this chromosomal region contains several other pater-Page 2 of 7
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NAs [27]. However, complementarity to a given mRNA
sequence has been reported for only HBII-52. The anti-
sense element of HBII-52 exhibits an 18-nt complementa-
rity to the 5-HT2C mRNA whereby it is subject to
posttranscriptional RNA editing and an alternatively
spliced exon Vb [27]. Subjects with Prader-Willi syn-
drome, a neurodevelopmental disorder involving a chro-
mosome 15q11 abnormality, have different 5-HT2C
mRNA processing than healthy individuals, which may
contribute to their clinical symptoms [28]. In an attempt
to identify targets for other orphan snoRNAs, we have
recently developed a computer program, snoTARGET
[29]. According to our initial analysis using snoTARGET,
there are potential target mRNAs for other orphan snoR-
NAs which need to be verified using molecular and func-
tional assays. This finding further suggests the importance
of exploring the role of snoRNAs in human diseases.
piRNA (Piwi-interacting RNAs) are a newly discovered
class of small RNAs, 26-31 nucleotides in length, that are
expressed abundantly in the spermatogenic cells [30]. The
majorities of piRNAs exist as clusters and occur on one or
both strands, designated as monodirectional or bidirec-
tional clusters, respectively. The biological function of
piRNAs is not fully known, but their expression pattern
indicates that they play roles in spermatogenesis and
germline development [30].
Small interfering RNAs (siRNAs) are about 21 nucleotides
in length and derive from double stranded RNA (dsRNA),
typically a result of transgenic, viral or other exogenous
dsRNA sources [31]. In addition to exogenous siRNAs,
there have been reports of endogenous siRNAs found in
plants, flies, and mammals [31]; however, endogenous
siRNAs in humans remain to be discovered. The siRNAs
consist of a guide strand and a passenger strand. The guide
strand binds to mRNA molecules resulting in a knock-
down in the levels of mRNA, protein or both [31]. Brief
analysis of the siRNA data available from the MIT siRNA
database, containing experimentally validated siRNAs
[32], showed that several autism candidate genes are tar-
gets of exogenous siRNAs.
Multiple classes of ncRNAs are highly represented in the
nervous system, emphasizing the likelihood that nervous
system development and function is heavily dependent
on RNA regulatory networks, and alterations of these net-
works may result in many neurological diseases. It is
thought that ncRNAs may provide the key to better under-
standing the etiology of human diseases, particularly neu-
rological diseases [33]. For example, dysregulation of
microRNAs has been reported in association with Alzhe-
imer's disease [34-36], Parkinson's disease [37], and
Tourette's syndrome [38]. More recently, a study con-
ducted by our group [39] and a report by Abu-Elneel et al.
[40] suggested that microRNAs should be evaluated in the
etiology of autism. Therefore, functional features and bio-
logical significance of ncRNAs suggests that this class of
gene regulatory factors should be considered in relation to
complex disorders.
Fragile sites are another important genomic factor in
human genetics. Fragile chromosome sites are nonran-
dom gaps or breaks of variable size that can appear spon-
taneously or after exposing the cells to chemical agents
[41,42]. Based on their frequency in the general popula-
tion, fragile sites can be classified into two main classes:
common and rare [42]. One rare fragile site (FRAXE) is
associated with a form of mental retardation and also has
been reported as the most common cause of autism
[43,44]. Analysis of the global distribution of fragile sites
and microRNAs in relation to genomic regions involved
in cancers indicated that microRNAs are frequently
located at fragile sites and cancer-associated genomic
regions [45]. These lines of evidence warrant the need for
further analysis of fragile sites in autism using an inte-
grated approach to gain more insight into the possible
role of this form of cytogenetic marker in relation to other
contributing genetic factors.
The growing list of autism susceptibility genetic factors
and the need to explore the role of gene regulatory ele-
ments (e.g., ncRNAs) warrants the implementation of bio-
informatics tools to facilitate a more comprehensive
approach evaluating this complex neurodevelopmental
disorder. In an effort to make all reported genomic fea-
tures associated with ASD (i.e., susceptibility genes and
CNVs) and their potential relationship with other
genomic features impacting on human disease (e.g.,
ncRNAs [23] and fragile sites [46]) accessible to the scien-
tific community, the Autism Genetic Database (AGD), a
freely available database, was designed by our research
group.
Construction and content
AGD is implemented as a mySQL (v5.0.51) http://
mysql.com relational database with the schema for the
AGD data organization available on the website. Its web
interface was implemented in Perl:CGI, and HTML with
the database query logic implemented in Perl:DBI. The
genome browser is a modified implementation of the
generic genome browser http://www.gmod.org. A descrip-
tion of the pipeline for data collection and integration is
depicted in Figure 1.
AGD stores the lists of autism susceptibility genes and
CNVs generated through scientific literature searches. For
the susceptibility genes, we included those with at least
one suggestive report for their association with autism.Page 3 of 7
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genes after reviewing 1228 articles obtained from PubMed
(August 2008) using the search key words "autism" and
"gene". The results were carefully evaluated by the PI
(Z.T.) and a three-level classification system was used for
autism susceptibility genes to reflect their level of associa-
tion according to the reviewed publications: 3>2>1
whereby category 3 represents the strongest autism candi-
date genes. This arbitrary classification of genes has been
added to provide a quick reference for the importance of
each gene in relation to autism while the users may decide
not to consider our classification.
For CNVs, those with at least one reported association
with ASD were included. De novo or familial status of each
CNV, as well as the subject's gender was included when-
ever such information was available in the reference
paper. Due to the lack of a standardized formal naming
convention for copy number variations that provides a
unique identifier for each CNV, an informal identifier has
been established for each of the CNVs associated with
ASD using the chromosomal band followed by a roman
numeral. One such example would be the CNV 17p12_III,
which is the third CNV that occurs in the chromosomal
band 17p12.
The snoRNA data was obtained using the sno/scaRNA
coordinate file (version hg18, NCBI Build 36.1) from sno-
RNA-LBME-db [47] and the microRNA data was obtained
using the miRBase sequence file (version 12.0) from miR-
Base [48]. piRNABank database was used as a source for
all known human piRNA [49]. Access to the data stored in
the piRNABank database was kindly provided by Dr.
Agrawal. The siRNA data was obtained from the MIT/ICBP
siRNA database (January 9, 2009 update) [32]. At this
point in time, only exogenous siRNAs have been discov-
ered for humans, in the event that endogenous human
siRNAs are discovered they will be incorporated into our
database. Also, because all current siRNAs arise from exog-
enous DNA sources, we only included those siRNA that
target autism susceptibility genes. A list of human fragile
sites was obtained from a review paper by Debacker and
Kooy [46] and their genomic locations were retrieved
from the UCSC genome browser (version hg18, NCBI
Build 36.1). Applying the above criteria resulted in a total
of 145 and 473 autism susceptibility genes and CNVs
respectively, plus 668,688 noncoding RNAs (667,774
piRNAs, 534 microRNAs, 374, snoRNAs, and 6 siRNAs)
and 120 human fragile sites, including rare fragile sites
(i.e., present in a small portion of the population) and
common fragile sites (i.e., present in all individuals),
grouped and organized by feature type in our database.
Due to the large number of piRNAs, the chromosomal
views in tabular form will not display piRNAs unless
explicitly selected.
Utility and discussion
In AGD, data is searchable and displayed in two formats:
query based tabular and genome browser. Both tools dis-
play the genes, CNVs, ncRNAs, and fragile sites in an eas-
ily accessible framework. A web-based tabular query tool
enables the user to start the search from any of the above
four categories of features. A combination of criteria can
then be employed to display other features within a user
specified distance of the selected factor's physical chromo-
somal location (Figure 2). Additional data relating to each
feature are provided through expanded tables and
through hyperlinks to the appropriate databases (e.g.,
PubMed, set to search with "gene name" and "autism"
which provides up-to-date literature search; and miRBase
for microRNAs) or literature references (e.g., for CNVs). In
addition to the tabular display of data, users may also
employ the customized genome browser based on the
Generic Genome Browser [50] to visualize the different
data tracks for the genes and CNVs related to autism as
well as their surrounding ncRNAs and fragile sites.
While databases to maintain both autism susceptibility
genes (AutDB [51]) and CNVs (Autism Chromosome
Rearrangement Database-ACRD [52]) have been recently
developed, the main function of these available resources
is to serve as a catalog of the relevant subset of autism
related genomic data. ACRD also offers the possibility to
visualize microRNAs in relation to autism associated
chromosomal abnormalities. However, in ACRD a query
begins with selecting a CNV and thus it does not allow a
flexible search tool as the one provided by AGD (i.e., to
Data flow diagram for Autism Genetic Database (AGD)Figure 1
Data flow diagram for Autism Genetic Database 
(AGD). External sources (yellow) are downloaded into 
AGD (blue). External data sources are also referenced from 
the Web client where applicable.Page 4 of 7
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ile site). AGD was designed as a repository for all reported
genetic features in association with autism, with the goal
of facilitating the elucidation of possible relationships
between known potential ASD elements and other genetic
features. Some of these features are not yet fully evaluated,
but are potentially important in the etiology of genetic
disorders, such as fragile sites and noncoding RNAs.
This new autism related data resource, AGD, will be rou-
tinely updated and upgraded as new information relating
to ASD becomes available. Current plans for future devel-
Online display of AGD search results in both the tabular and the genome browser formats for the region surrounding the NRXN1 gene on chromosome 2Figure 2
Online display of AGD search results in both the tabular and the genome browser formats for the region sur-
rounding the NRXN1 gene on chromosome 2. The tabular display includes an example usage flow indicating the scheme 
to follow (shown by numbers 1 to 5) when using the database.Page 5 of 7
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allowing users to correlate currently stored information
with linkage analysis studies and noncoding RNA gene
targets. Additionally, plans are being formalized to add
SNP information into the AGD database expanding
search functions and application of this autism resource
for the research community.
Conclusion
The Autism Genetic Database is a repository resource
incorporating all reported autism susceptibility genes and
CNVs integrated with the known human noncoding RNAs
and fragile sites. The scope of the AGD database distin-
guishes it from other recently developed data catalogs
(i.e., AutDB [51] and ACRD [52]) by incorporating non-
ASD genetic factors relevant to human diseases, particu-
larly in complex disorders. Such a comprehensive reposi-
tory for genomic information relating to ASD is crucial for
the advancement of computational research into the field.
The web interface provided by our program enables
researchers, for example, to quickly identify specific
ncRNAs within or close to reported autism candidate
genes or CNVs in a subset of autistic subjects with com-
mon multiple subtle genomic features. Furthermore, the
availability of such an integrated and comprehensive
database provides a valuable opportunity to explore and
test certain autism genetic models.
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